Passage BIO, Inc. — Investor Relations & Filings
Filings indexed
414
across all filing types
Latest filing
2026-05-27
Regulatory Filings
Country
US
United States of America
Listing
US
PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| FORM 8-K | 2026-05-26 | English | |
| 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | |
| ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 47845684 | 8-K | 2026-05-27 | English | ||
| 47059730 | FORM 8-K | 2026-05-26 | English | ||
| 45232728 | 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | ||
| 37959866 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | ||
| 34690715 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | ||
| 33703026 | ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 33703035 | DEF 14A - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 32979094 | 4 - Passage BIO, Inc. (0001787297) (Issuer) | 2026-03-18 | English | ||
| 32898268 | 10-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 32898267 | 8-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 13203760 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203761 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203762 | FORM 8-K | 2026-01-12 | English | ||
| 13203764 | Regulatory Filings 2026 | 2026-01-09 | English | ||
|
2025
1 filing
| |||||
| 13203763 | Director's Dealing 2025 | 2025-12-29 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Q32 Bio Inc.
A clinical-stage biotech developing therapies for autoimmun…
|
QTTB | US | Professional, scientific and te… |
|
QinetiQ Group PLC
A science and engineering company providing technology for …
|
GB | Professional, scientific and te… | |
|
Qualigen Therapeutics, Inc.
Clinical-stage biotech developing novel cancer treatments f…
|
QLGN | US | Professional, scientific and te… |
|
Quanterix Corp
Digitizes biomarker analysis with an ultra-sensitive digita…
|
QTRX | US | Professional, scientific and te… |
|
Quantum Base Holdings PLC
Develops quantum-secure fingerprints for product authentica…
|
QUBE | GB | Professional, scientific and te… |
|
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC
An R&D company using AI and quantum computing to enhance Bi…
|
QBT | GB | Professional, scientific and te… |
|
Quantumzyme Corp.
A biotransformation company specializing in enzyme engineer…
|
QTZM | US | Professional, scientific and te… |
|
QUIA PHARMA AB
Develops medicines using a proprietary drug delivery platfo…
|
QUIA | SE | Professional, scientific and te… |
|
Qurient Co., Ltd.
Clinical-stage biopharma developing drugs for oncology, cGv…
|
115180 | KR | Professional, scientific and te… |
|
RACURA ONCOLOGY LTD
Clinical-stage developer of precision oncology therapeutics…
|
RAC | AU | Professional, scientific and te… |
Passage BIO, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34849/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34849 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34849 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34849 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34849}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Passage BIO, Inc. (id: 34849)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.